Free Design Audit Available - Click Here for Details

Quibim adds new AI cancer detection capability to prostate tool

Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

As MRI scans have become standard-of-care for prostate cancer, and populations at higher risk of the disease continue to grow, many radiology departments have not had the proper resources in place to handle the avalanche of advanced medical imagery needing to be analysed to appropriately manage prostate cancer patients. QP-prostate, one of Quibim’s flagship products, was developed to overcome this challenge by using AI to speed up the processing of images, increase the accuracy of radiologists who identify signs of cancer and help them pass on actionable data points to oncology departments.

QP-Prostate stands out in the market as it speeds up processes without compromising on quality, with a validated international study showing that the software efficiently segments imagery of the prostate gland with 88% accuracy. The algorithm also segments key subregions and zones and calculates prostate volume, aiding in prostate-specific antigen density calculations and fusion biopsy planning.

From this year, QP-Prostate can also be used by EU and UK clinicians for AI-driven lesion detection thanks to algorithms trained with post-biopsy pathology data as ground truth, rather than radiology assessments. This is an industry-first and will help radiologists enhance diagnostic accuracy in terms of high specificity beyond high sensitivity as well as shortened reporting times

Sign up for Blog Updates